CD274 and head and neck squamous cell carcinoma: Clinical trials show that patients with HNSCC can benefit from programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapy (one type of ICI) and obtain a better quality of life (Leemans et al., 2018; Cramer et al., 2019).